PHARMACOKINETICS OF RECOMBINANT-HUMAN-ERYTHROPOIETIN APPLIED SUBCUTANEOUSLY TO CHILDREN WITH CHRONIC-RENAL-FAILURE

被引：10

作者：

BRAUN, A ^{[1
]}

DING, R ^{[1
]}

SEIDEL, C ^{[1
]}

FIES, T ^{[1
]}

KURTZ, A ^{[1
]}

SCHARER, K ^{[1
]}

机构：

[1] UNIV HEIDELBERG,KINDERKLIN,SEKT PADIAT NEPHROL,NEUENHEIMER FELD 150,W-6900 HEIDELBERG,GERMANY

来源：

PEDIATRIC NEPHROLOGY | 1993年 / 7卷 / 01期

关键词：

ANEMIA; CHRONIC RENAL FAILURE; ERYTHROPOIETIN; PHARMACOKINETICS;

D O I：

10.1007/BF00861571

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

The single-dose pharmacokinetics of recombinant human erythropoietin (rHuEPO) given SC was investigated in 20 patients aged 7-20 years at different stages of chronic renal failure. In a pilot study we confirmed the lower bioavailability of the drug in 2 children when given SC compared with the IV route (24% and 43%, respectively). Following administration of 4,000 units/M2, rHuEPO SC effective serum erythropoietin concentrations increased from a mean baseline level (+/-SD) of 23+/-13 units/l to a mean peak concentration of 265+/-123 units/l, which was reached after 14.3+/-9.4 h, followed by a slow decline until baseline values were attained at 72 h. Mean residence time was 30+/-9 h and mean elimination half-time 14.3+/-7 h. The single-dose kinetics of SC rHuEPO in children with different degrees of renal failure are comparable to those in adult patients. Possibly, the higher efficacy of SC rHuEPO in patients with renal anaemia compared with IV rHuEPO is related to its prolonged action.

引用

页码：61 / 64

页数：4

共 31 条

[1]

Eschbach J.W., Adaon J.W., Anemia of end-stage renal disease, Kidney Int, 28, pp. 1-5, (1985)

[2]

Scharer K., Muller-Wiefel D.E., Complications of renal failure. Haematological complications, Pediatric nephrology, pp. 880-887, (1987)

[3]

Nissenson A.R., Nimer S.D., Wolcott D.L., Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects, Ann Intern Med, 114, pp. 402-416, (1991)

[4]

Sinai-Trieman L., Salusky I.B., Fine R.N., Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis, J Pediatr, 114, pp. 550-554, (1989)

[5]

Montini G., Zacchello G., Baraldi E., Zanconato S., Suppiej A., Fabris F., Andreetta B., Pavanello L., Zacchello F., Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis, J Pediatr, 117, pp. 556-560, (1990)

[6]

Rigden S.P.A., Montini G., Morris M., Clark K.G.A., Haycock G.B., Chantler C., Hill R.C., Recombinant human erythropoietin therapy in children maintained by haemodialysis, Pediatr Nephrol, 4, pp. 618-622, (1990)

[7]

Offner G., Hoyer P.F., Latta K., Winkler L., Brodehl J., Scigalla P., One year's experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis, Pediatr Nephrol, 4, pp. 498-500, (1990)

[8]

Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease, Contrib Nephrol, 88, pp. 201-211, (1991)

[9]

Warady B.A., Sabarth R.J., Smith C.A., Alon U., Hellerstein S., Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis, Pediatr Nephrol, 5, pp. 718-723, (1991)

[10]

Macdougall I.C., Roberts D.E., Naubert P., Dhermasena A.D., Coles G.A., Willia J.D., Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis, Lancet, 1, pp. 425-427, (1989)

← 1 2 3 4 →